A correction has been published 1
Given the worldwide increase in obesity, with attendant coexisting conditions and increased risk of death, there is a pressing need to address weight loss and maintenance strategies.1-3 Behavioral methods of weight control fail more often than not, and bariatric surgery is invasive and, often, eventually followed by regain of weight.1-3 Medications approved for weight loss by the Food and Drug Administration, the European Medicines Agency, and other regulatory bodies have had a troubling history, with withdrawal of several approved drugs owing to serious adverse events; among these are various amphetamines (addiction), fenfluramine (cardiac toxicity), and, most recently, lorcaserin (cancer risk).4,5 . . .
Funding and Disclosures
Disclosure forms provided by the authors are available with the full text of this editorial at NEJM.org.
This editorial was published on February 10, 2021, and last updated on June 29, 2021, at NEJM.org.
Print Subscriber? Activate your online access.